Vor Biopharma (NASDAQ:VOR) Earns Overweight Rating from Analysts at JPMorgan Chase & Co.

by · The Markets Daily

JPMorgan Chase & Co. began coverage on shares of Vor Biopharma (NASDAQ:VOR – Free Report) in a research note published on Tuesday morning, Marketbeat reports. The brokerage issued an overweight rating and a $43.00 price objective on the stock.

Other analysts have also issued reports about the stock. HC Wainwright reduced their price target on shares of Vor Biopharma from $55.00 to $32.00 and set a “buy” rating for the company in a research note on Friday, November 14th. Stifel Nicolaus upgraded Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 target price for the company in a research report on Wednesday, September 24th. Baird R W raised Vor Biopharma from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 15th. Wedbush assumed coverage on Vor Biopharma in a research note on Tuesday, November 25th. They issued a “neutral” rating on the stock. Finally, Robert W. Baird upgraded Vor Biopharma from a “neutral” rating to an “outperform” rating and upped their price objective for the company from $20.00 to $64.00 in a report on Wednesday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $68.86.

Get Our Latest Research Report on VOR

Vor Biopharma Stock Performance

NASDAQ:VOR opened at $12.13 on Tuesday. Vor Biopharma has a 1 year low of $2.62 and a 1 year high of $65.80. The company has a market capitalization of $126.27 million, a PE ratio of -0.03 and a beta of 2.08. The stock has a fifty day simple moving average of $18.93.

Insiders Place Their Bets

In other Vor Biopharma news, Director Ra Capital Management, L.P. sold 24,579 shares of the firm’s stock in a transaction dated Thursday, October 30th. The stock was sold at an average price of $25.12, for a total transaction of $617,424.48. Following the transaction, the director directly owned 779,652 shares in the company, valued at $19,584,858.24. This trade represents a 3.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Reprogrammed Interchange Llc sold 11,616 shares of the business’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $30.05, for a total value of $349,060.80. Following the completion of the sale, the insider directly owned 1,167,109 shares of the company’s stock, valued at $35,071,625.45. This represents a 0.99% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 2,164,441 shares of company stock valued at $51,550,549 over the last quarter. 0.45% of the stock is currently owned by corporate insiders.

Institutional Trading of Vor Biopharma

Several hedge funds have recently added to or reduced their stakes in VOR. Fcpm Iii Services B.V. acquired a new stake in shares of Vor Biopharma during the 3rd quarter valued at about $18,496,000. Jane Street Group LLC acquired a new position in Vor Biopharma in the first quarter worth about $140,000. OMERS ADMINISTRATION Corp bought a new position in Vor Biopharma during the first quarter worth about $100,000. Ariose Capital Management Ltd acquired a new stake in Vor Biopharma during the third quarter valued at approximately $5,368,000. Finally, Goldman Sachs Group Inc. grew its stake in shares of Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after purchasing an additional 58,247 shares during the period. Institutional investors own 97.29% of the company’s stock.

About Vor Biopharma

(Get Free Report)

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.

See Also